How to Build a TRT Protocol: Everything You Need to Know (2026 Guide)

Executive Summary

Testosterone replacement therapy is not a single drug — it is a protocol. A system of interlocking decisions, each influencing the others: which testosterone formulation you use, how frequently you inject, whether you add hCG to preserve fertility and testicular function, how you manage estrogen conversion, which labs you monitor and how often, and which provider has the infrastructure to actually manage that complexity well. Most TRT guides address one piece at a time. This guide covers the complete picture in sequence, so you understand how the pieces connect — and links to the deep-dive articles for each decision when you need full clinical detail.

The goal of a well-built TRT protocol is not the highest possible testosterone level. It is the stable, physiological testosterone level where symptoms resolve, side effects are minimized, and you can stay on the protocol indefinitely without accumulating downstream problems. That goal requires getting each component right — not just getting the prescription. For an overview of what testosterone replacement therapy is and how to qualify, see how to get testosterone prescribed online. For the full side-effect landscape, see TRT side effects.

At-a-Glance Comparison

Core TRT protocol components and the primary decision factor for each. Most men on well-managed TRT require all six components to be explicitly decided — even if the decision is 'not needed right now.' Updated March 2026.

Component 1: Diagnosis and Qualifying for TRT — What the Labs Actually Need to Show

Before any protocol decision can be made, the diagnosis has to be correct. TRT is indicated for confirmed hypogonadism — not for testosterone levels in the low-normal range in asymptomatic men, and not based on a single morning lab draw. The qualification criteria determine whether you should be on TRT at all, and they also determine which treatment path is right: exogenous testosterone, a SERM (enclomiphene/clomiphene), or an hCG-only protocol. Buyers searching for trt protocol usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The standard diagnostic framework requires two things: symptomatic low testosterone (fatigue, reduced libido, sexual dysfunction, mood changes, loss of muscle mass, increased body fat, cognitive symptoms) AND confirmed low serum testosterone on at least two morning fasting draws on separate days. A single low result is not sufficient. Clinical guidelines (Endocrine Society, AUA) use a threshold of approximately 300 ng/dL total T for consideration of treatment, though this is a soft boundary — some men are symptomatic in the 300–400 ng/dL range and some are not. The more clinically meaningful measurement is free testosterone (not bound to SHBG), because SHBG (sex hormone-binding globulin) levels vary widely between men and determine how much testosterone is actually bioavailable to tissues. A man with total T of 450 ng/dL and very high SHBG may have free T in the hypogonadal range. Complete baseline labs before TRT: total testosterone (morning, fasting); free testosterone (calculated or equilibrium dialysis); SHBG; LH (luteinizing hormone) and FSH (follicle-stimulating hormone) — these differentiate primary hypogonadism (testicular failure: low T, high LH/FSH) from secondary hypogonadism (hypothalamic-pituitary dysfunction: low T, low or inappropriately normal LH/FSH); sensitive estradiol (LC/MS-MS); complete blood count (CBC) — baseline HCT before starting; PSA (if 40+); comprehensive metabolic panel; prolactin and thyroid if secondary hypogonadism is suspected. The LH/FSH result is structurally important: secondary hypogonadism (low LH/FSH) is potentially reversible with SERM therapy (enclomiphene or clomiphene) and preserves the hypothalamic-pituitary-testicular (HPT) axis rather than suppressing it. For men with secondary hypogonadism who want to preserve fertility and testicular function, enclomiphene is often the preferred first-line approach — see enclomiphene vs TRT for the complete decision framework. For diagnostic interpretation, see how to read testosterone lab results, what is a good testosterone level, and primary vs. secondary hypogonadism. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Starting TRT without baseline LH/FSH is the most consequential diagnostic gap. Without knowing whether hypogonadism is primary or secondary, you may be treating an upstream problem (hypothalamic/pituitary dysfunction) with downstream exogenous testosterone — when the appropriate treatment would be a SERM that restores the axis. You also forgo the fertility-preserving window that SERM therapy offers for secondary hypogonadism. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Component 2: Choosing Your TRT Formulation — Injectable, Oral, Topical, or Pellets

Testosterone is available in multiple delivery formats, each with different kinetics, cost structures, dosing precision characteristics, and practical tradeoffs. For most men starting TRT in 2026, the choice narrows quickly — but understanding why you are on a particular formulation (rather than just accepting what the clinic defaults to) allows you to advocate for changes if the initial choice is not working. Buyers searching for trt protocol usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Injectable testosterone (cypionate or enanthate) is the most common and most flexible option for most men. Both are esterified testosterone dissolved in oil that releases over days from the injection depot. Cypionate has a half-life of approximately 8 days; enanthate approximately 4–5 days. The practical difference for most TRT patients is negligible — they are functionally interchangeable for TRT purposes — though availability and cost can differ (cypionate is the dominant US formulation; enanthate is more common in Europe and may be relevant during pharmacy shortages). See testosterone cypionate vs. enanthate for the complete ester comparison. Injectable testosterone offers the best dosing precision of any formulation — you control the dose to the milligram, adjust frequency easily, and can modulate your peak-trough curve by changing how often you inject. Injection route (SubQ vs IM): Injectable testosterone can be delivered intramuscularly (glute, quad, lateral thigh) or subcutaneously (belly fat, outer thigh) using an insulin-gauge needle. SubQ produces flatter kinetics — lower peak, higher trough, more stable serum levels — compared to the higher-peak IM route. SubQ has been associated with lower HCT and E2 elevation in published studies, which is clinically meaningful for men who aromatize heavily or run high hematocrit. For the complete SubQ vs IM comparison, see subcutaneous vs. intramuscular TRT. Oral testosterone (Kyzatrex): FDA-approved lymphatic-absorption oral testosterone that bypasses first-pass hepatic metabolism. Dosed twice daily, requires fatty meal for absorption. Produces more variable peaks than injectables but avoids injections entirely — meaningful for patients with needle anxiety or injection site complications. Available primarily through select telehealth providers including Hims (branded as their oral TRT option). Topical creams and gels: Testosterone cream/gel applied to skin (inner wrist, shoulder, inner arm, or scrotal skin for higher absorption). Convenient but produce significant inter-day variability and carry a transfer risk to partners and children. Pellets (Testopel): surgical insertion under skin every 3–6 months; produces stable levels but dosing cannot be adjusted once inserted. Pellets are the least flexible option for protocol optimization. For the delivery method comparison, see testosterone cream vs. injections vs. pellets. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most common formulation selection error is defaulting to the cheapest or most convenient option without considering how it fits your specific risk factors. Men with higher hematocrit, higher E2 aromatization, or fertility preservation needs are often better served by SubQ injectables at higher frequency — even if IM once-weekly is the platform's default offering. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Component 3: Dosing and Frequency — Building Your Target Level and Managing Peak/Trough

The dose of testosterone in your protocol determines where your serum testosterone stabilizes. The frequency of dosing determines the shape of the curve around that level — whether you experience significant peaks and troughs or a flat, stable level. Both matter: your target level affects symptom resolution, and the shape of the curve affects side effects including E2, HCT, and injection-site symptoms. Buyers searching for trt protocol usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

For injectable testosterone, most online TRT clinics in 2026 start men in the 80–140 mg/week range of testosterone cypionate, split across 1–3 injections depending on the protocol. The Endocrine Society dosing guidelines for hypogonadism target mid-range total testosterone of approximately 400–700 ng/dL, with free testosterone in the upper-normal range. Practically, most men report symptom resolution in the 500–800 ng/dL total T range, though optimal levels are individual — some men feel best at 600 ng/dL and some at 900 ng/dL. Why frequency matters more than most patients expect: Testosterone cypionate injected once weekly produces a predictable saw-tooth curve: serum T peaks at 24–48 hours post-injection (typically 800–1,200 ng/dL in most protocols), then declines through the week to a trough at day 6–7 (often 300–400 ng/dL). That wide swing means: higher peak aromatization → higher peak E2 → more aromatase inhibitor pressure; and higher peak hematocrit stimulation from the testosterone peak → elevated HCT risk. Injecting twice weekly (e.g., Mon/Thu) splits the same weekly dose into two smaller shots, narrowing the peak-trough difference by roughly 40–50%. This is the most underutilized protocol optimization: many men who are struggling with E2 management or borderline HCT on once-weekly dosing normalize both markers simply by switching to twice-weekly without any other change. Frequency optimization for SubQ: Some men use every-other-day or daily SubQ micro-doses (e.g., 20 mg/day via insulin syringe) for the flattest possible kinetics. This is common in men who are highly sensitive to peak-related aromatization or who microdose to minimize HCT drift. How long TRT takes to stabilize: Steady-state serum testosterone requires approximately 4–5 half-lives to reach equilibrium after a dose change — roughly 6–8 weeks for testosterone cypionate. Do not interpret labs taken earlier than 6 weeks after a dose change as representative of your new steady state. See how long does TRT take to work for the full timeline of results by symptom category. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most common dosing error is chasing a lab number rather than a symptom response. Protocols that push total testosterone above 1,000–1,200 ng/dL to optimize body composition accelerate HCT elevation, estrogen aromatization, and the pace of testicular atrophy — without proportional clinical benefit for most men. The therapeutic window for TRT is broad; the goal is stable improvement in the physiological range, not supraphysiological optimization. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Component 4: Adjunct Medications — When and How to Add hCG/Gonadorelin and Anastrozole

Two medications are commonly added to TRT protocols as adjuncts: hCG (or its functional substitute gonadorelin) to preserve the HPT axis and intratesticular testosterone, and anastrozole to manage estradiol elevation. Both are sometimes reflexively prescribed and sometimes reflexively avoided. The correct framework is individual: add them when the specific indication is present, and not before. Buyers searching for trt protocol usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

hCG and gonadorelin — the HPT axis preservers: Exogenous TRT suppresses the hypothalamic-pituitary-testicular axis. The pituitary stops signaling the testes (LH/FSH go to near-zero), intratesticular testosterone production declines, and the testes atrophy. For men on TRT indefinitely without hCG, testicular atrophy is universal and intratesticular testosterone can drop 90%+ below baseline. hCG (human chorionic gonadotropin) mimics LH at the Leydig cell receptor, stimulating intratesticular testosterone production and maintaining testicular volume and spermatogenesis signaling. Standard protocol: 250–500 IU subcutaneous, 2–3× per week alongside TRT. hCG substantially improves sperm count maintenance on TRT compared to TRT alone. Gonadorelin is a GnRH analog that stimulates pituitary LH/FSH release, which then signals the testes. Used at 100–200 mcg 2–3× weekly. Some providers use gonadorelin as a compounded replacement for hCG due to supply and cost advantages; clinical evidence for gonadorelin in TRT adjunct protocols is emerging but less established than the hCG evidence base. Who needs it: Any man who (1) has fertility plans now or may in the future, (2) wants to preserve testicular volume and function, (3) is concerned about HPT axis suppression, or (4) may need to pause TRT for any reason. See TRT and hCG: how the protocol works and TRT and fertility for the complete clinical evidence and protocol details. Anastrozole — estradiol management: Anastrozole blocks aromatase, reducing testosterone-to-estradiol conversion. It is indicated when elevated estradiol (confirmed on a sensitive assay, not a standard immunoassay) is causing specific symptoms: true gynecomastia, significant nipple tenderness, estrogen-driven water retention, or estrogen-mediated mood changes. It is NOT indicated for elevated lab values in asymptomatic men. Over-prescribing anastrozole is one of the most common protocol errors in the online TRT industry — it causes iatrogenic estrogen deficiency with severe joint pain, crashed libido, depression, and long-term bone density loss. Protocol optimization (increased injection frequency, dose reduction, body composition improvement) should precede anastrozole. When anastrozole is genuinely needed: start at 0.25 mg 1–2× weekly, recheck sensitive E2 at 6 weeks, target 20–35 pg/mL. See anastrozole on TRT: when you actually need it for the complete evidence-based framework. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The two most common adjunct errors are: (1) adding anastrozole reflexively to every protocol without individual E2 labs and symptoms — which causes over-suppression — and (2) not offering hCG to men with fertility intentions before their sperm count is affected. Both errors are preventable with the right provider infrastructure. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Component 5: Monitoring Your Protocol — Labs, Timeline, and What to Track

TRT is a long-term therapy that requires ongoing monitoring to remain safe and effective. The monitoring schedule is not optional — it is the mechanism by which dose-limiting complications (HCT elevation, PSA changes, lipid effects) are caught early, protocol optimization is evidence-based rather than guesswork, and your provider can demonstrate clinical competence beyond writing the initial prescription. Buyers searching for trt protocol usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Pre-treatment baseline: Full panel as described in the diagnosis section. Establish your baseline HCT, PSA, lipid panel, CBC, and hormone profile before any testosterone is introduced. 6-week follow-up: The first post-initiation lab draw should happen at approximately 6 weeks — the point at which cypionate/enanthate reaches steady-state. Draw mid-cycle (between injections), on the same day of the week, fasting in the morning. What to measure: total T, free T, sensitive E2, CBC (especially HCT), PSA, CMP. This panel tells you whether your dose is achieving the target T range, whether E2 needs management, and whether HCT has begun to climb. Hematocrit (HCT) monitoring is non-negotiable: TRT stimulates erythropoiesis (red blood cell production) via direct EPO stimulation and iron mobilization. HCT elevation is dose-dependent, more pronounced with higher peaks (less frequent injection → higher peaks → more HCT stimulation), and can progress to clinically significant polycythemia (HCT ≥52–54%) which increases blood viscosity and thromboembolic risk. HCT above 52–54% is a standard threshold for dose reduction, frequency optimization, or therapeutic phlebotomy. Quarterly monitoring once stable: After the 6-week draw confirms appropriate levels and no safety concerns, quarterly labs (every 3 months) are the standard of care. Many providers are flexible on this after 1+ year of stability, extending to every 6 months — but annual monitoring is insufficient for an ongoing hormonal intervention. PSA monitoring: TRT does not cause prostate cancer, but it stimulates the prostate and can unmask pre-existing cancer. Baseline PSA before starting and annual PSA monitoring are recommended for men 40 and older; any PSA velocity increase of >1.4 ng/mL in a year warrants urology referral regardless of absolute value. What a complete quarterly panel includes: Total testosterone and free testosterone; sensitive estradiol (LC/MS-MS); CBC with differential (HCT, hemoglobin, RBC); comprehensive metabolic panel (CMP); PSA (if 40+); lipid panel (TRT has favorable effects on body composition but variable effects on lipids — HDL can decrease modestly); and LH/FSH if you are on hCG (to confirm testicular stimulation without over-suppression of the pituitary). See how to read testosterone lab results for interpreting all panels in context. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most dangerous gap in TRT monitoring is a provider who writes the initial prescription and then monitors only annually — or not at all. HCT can climb to polycythemia-range levels within 6 months on some protocols. A man going 12 months without a CBC on TRT is accumulating HCT risk without a safety check. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Component 6: Choosing the Right Provider for Your Protocol Complexity

The provider you choose determines the quality of every component of your protocol — the diagnostic rigor, the formulation options available to you, whether adjuncts like hCG are accessible, how E2 is monitored and managed, and how quickly problems are addressed. Provider selection is not just a cost decision; it is the infrastructure decision that determines whether your TRT protocol can actually be managed well. Buyers searching for trt protocol usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The online TRT market in 2026 divides roughly into three tiers. Tier 1 — Specialist TRT clinics: Defy Medical, Marek Health, Hone Health, and similar specialist practices offer the most comprehensive protocol management. They use sensitive estradiol as standard, offer hCG and gonadorelin as accessible adjuncts, prescribe anastrozole based on individual response rather than protocol defaults, have clinician availability for protocol adjustments, and order comprehensive quarterly panels. Cost: typically $200–$450+/month including medications and labs. Appropriate for men with complex protocols, fertility considerations, or those who have been through protocol iterations at simpler platforms and need more individualized care. Tier 2 — Mid-tier telehealth: Maximus Tribe, TRT Nation, and similar providers offer a solid middle ground — better monitoring and more protocol flexibility than Tier 3, at lower cost than Tier 1. Maximus specifically promotes twice-weekly SubQ micro-dosing as their default delivery (which improves kinetics vs once-weekly IM), uses sensitive E2, and can prescribe anastrozole based on individual labs. Cost: $150–$250/month. Appropriate for most men seeking a balance of clinical quality and cost efficiency. Tier 3 — Consumer telehealth: Hims, Roman, and similar platforms optimize for ease of enrollment and low overhead. They offer TRT (note: Hims currently prescribes Kyzatrex oral or enclomiphene, NOT injectable testosterone, for most patients — see does Hims offer TRT for the current status), but protocol flexibility is limited and monitoring rigor is typically lower. Standard immunoassay rather than sensitive E2 is more common. Appropriate for men with straightforward presentations who do not anticipate needing hCG, complex E2 management, or non-standard protocols. For the full comparison: best online TRT clinics compared 2026, Hims vs. Roman vs. Maximus. For the enclomiphene pathway: best online enclomiphene clinics 2026. Cost context: TRT costs vary substantially by formulation, provider tier, pharmacy, and insurance status. Total annual cost at consumer telehealth can run $1,200–$2,400; at mid-tier $1,800–$3,000; at specialist clinics $2,400–$5,400+. See how much does TRT cost in 2026 for the full breakdown by provider and formulation. If you need to switch providers — due to cost, service quality, or protocol needs — see how to switch TRT providers without a treatment gap for the complete logistics. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The practical cost of choosing the wrong provider tier is not the monthly bill — it is the accumulated protocol errors and monitoring gaps. Men who spend 12–18 months on a consumer platform with poor monitoring, reflexive anastrozole, and no hCG access often arrive at a specialist clinic with suppressed fertility, an over-suppression crash history, and a monitoring data gap that makes protocol re-optimization harder. Starting in the right tier for your situation saves time and clinical risk, not just money. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

Ready to build your TRT protocol — or optimize the one you're already on? Our provider comparison tool lets you filter clinics by protocol features: sensitive E2 assay, hCG/gonadorelin access, SubQ injection support, monitoring frequency, and price range. Find the right provider for where your protocol actually needs to go.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is a TRT protocol?

A TRT (testosterone replacement therapy) protocol is the complete, individualized treatment plan for testosterone deficiency: it covers which testosterone formulation you use, the dose and frequency, the injection route (subcutaneous vs intramuscular), any adjunct medications (hCG/gonadorelin for fertility preservation, anastrozole for estrogen management), the lab monitoring schedule, and how protocol adjustments are made over time. A protocol is not just a prescription — it is the ongoing management system that determines whether TRT achieves its goals safely.

What labs do I need before starting TRT?

A complete pre-TRT panel should include: two morning fasting total testosterone draws on separate days; free testosterone; SHBG; LH and FSH (to distinguish primary vs secondary hypogonadism); sensitive estradiol (LC/MS-MS); complete blood count (CBC) for baseline HCT; PSA (if 40+); comprehensive metabolic panel; and lipid panel. LH and FSH are particularly important — they determine whether exogenous TRT or a SERM (enclomiphene) is the appropriate treatment.

How long does it take for TRT to work?

TRT produces results on different symptom categories at different timelines. Libido and energy often improve within 3–6 weeks. Mood and motivation typically follow at 6–12 weeks. Body composition changes (lean mass gain, fat loss) require 3–6+ months to become measurable. Sexual function, including morning erections and erectile quality, often lags 6–12 weeks behind initial symptom relief. The full protocol stabilization takes approximately 3–6 months. For a timeline by symptom category, see the complete guide on how long TRT takes to work.

What is the best TRT injection frequency?

Twice-weekly injections are the most commonly recommended frequency for testosterone cypionate or enanthate — they balance the practical burden of injection against the clinical benefit of narrowing the peak-trough curve. More frequent injection (every other day, daily SubQ microdosing) is appropriate for men who are particularly sensitive to peak-related estradiol elevation or HCT stimulation. Once-weekly injections are the simplest but produce the widest swings and the most E2/HCT pressure — many protocol problems resolve simply by switching from once-weekly to twice-weekly without any other change.

Do I need anastrozole on TRT?

Most men do not. Anastrozole is only warranted when genuinely elevated estradiol (confirmed on a sensitive LC/MS-MS assay) is causing specific symptoms — true gynecomastia, significant nipple tenderness, or estrogen-mediated mood changes. Asymptomatic estradiol elevation does not require treatment. The first-line intervention for elevated E2 is protocol optimization (increase injection frequency, modest dose reduction, body composition improvement) — not medication. Reflexive anastrozole prescribing without individual symptom and lab confirmation is one of the most common sources of protocol harm in the online TRT industry.

What is hCG used for on TRT?

hCG (human chorionic gonadotropin) mimics LH at the testicular Leydig cell receptor, stimulating intratesticular testosterone production and maintaining spermatogenesis signaling. On TRT without hCG, the pituitary stops producing LH/FSH (suppressed by the exogenous testosterone), intratesticular testosterone drops dramatically, and testicular atrophy occurs. hCG reverses this: it maintains testicular volume and substantially improves sperm count retention compared to TRT alone. It is recommended for any man with fertility considerations or who wants to preserve testicular function on TRT.

What hematocrit level is too high on TRT?

A hematocrit (HCT) at or above 52–54% is the standard threshold for clinical concern on TRT. Elevated HCT increases blood viscosity and thromboembolic risk. The appropriate response is protocol optimization first — lower dose, more frequent injections to reduce EPO-stimulating peaks, or a switch to subcutaneous injection route (which produces lower HCT elevation than IM per published data). Therapeutic phlebotomy is appropriate if HCT is significantly elevated, but addressing the protocol driver prevents the need for recurring phlebotomy.

How often should I get labs on TRT?

Baseline labs before starting; a 6-week follow-up after protocol initiation (minimum: total T, sensitive E2, CBC/HCT, PSA if 40+); quarterly labs for at least the first 12 months; and every 6 months once stable on a consistent protocol with normal values. Any protocol change (dose, frequency, formulation switch, new adjunct) should trigger a new lab draw at 6 weeks. Annual monitoring is insufficient for an ongoing hormonal intervention.

What is the difference between primary and secondary hypogonadism, and why does it matter for TRT?

Primary hypogonadism is testicular failure — the testes cannot produce adequate testosterone even with full LH/FSH signaling from the pituitary. LH and FSH are elevated (the pituitary is calling for more testosterone production but not getting a response). Secondary hypogonadism is upstream dysfunction — the hypothalamus or pituitary is not signaling adequately, so LH/FSH are low or inappropriately normal. Secondary hypogonadism is potentially reversible with SERM therapy (enclomiphene, clomiphene) that stimulates LH/FSH release. Men with secondary hypogonadism who choose SERM over TRT preserve the HPT axis and fertility — exogenous TRT suppresses LH/FSH entirely and is not reversible without a TRT-to-SERM transition.

Which online TRT provider is best for a complex protocol?

For protocols requiring hCG, sensitive estradiol management, SubQ option, and individualized titration: Defy Medical and Marek Health are the strongest for protocol depth and individualized management. Maximus Tribe is a strong mid-tier option with SubQ support, sensitive E2, and protocol flexibility at a lower price point. Hims and Roman work well for straightforward, low-complexity protocols but are less equipped for nuanced estrogen management or adjunct prescribing. Use the provider comparison tool to filter by the specific protocol features you need.